МОДЕЛЮВАННЯ ЗАГАЗОВАНОСТІ СУСПІЛЬНОГО ПРИМІЩЕННЯ ТОКСИЧНИМ ГАЗОМ

The 2D numerical model to simulate the pollutant dispersion in public compartments is offered. The model is based on the equation of potential flow and the equation of admixture transfer. The results of numerical experiment are presented.На базе модели потенциального течения и модели переноса примеси предложена 2D численная модель для прогноза уровня загрязнения в общественных помещениях. Представлены результаты численного моделирования.На базі моделі потенціальної течії та моделі переносу домішки запропоновано 2D чисельну модель для прогнозування забруднення в приміщеннях. Наведено результати розрахунків на базі розробленої моделі

NUMERICAL SIMULATION OF THE TERRITORY FLOODING PROCESS

A numerical model to calculate the process of ground waters rise has been proposed. The model is based on the 2-D equations of filtration. The results of numerical experiment are presented

MODELING OF GASEOUSNESS OF PUBLIC PREMISES WITH TOXIC GAS

The 2D numerical model to simulate the pollutant dispersion in public compartments is offered. The model is based on the equation of potential flow and the equation of admixture transfer. The results of numerical experiment are presented

ЧИСЕЛЬНЕ МОДЕЛЮВАННЯ ПРОЦЕСУ ПІДТОПЛЕННЯ ТЕРИТОРІЇ

A numerical model to calculate the process of ground waters rise has been proposed. The model is based on the 2-D equations of filtration. The results of numerical experiment are presented.Разработана численная модель расчета процесса подтопления территории. Модель основывается на решении двухмерных уравнений фильтрации. Приводятся результаты вычислительного эксперимента.Розроблена чисельна модель розрахунку процесу підтоплення території. Модель базується на рішенні двовимірного рівняння фільтрації. Наводяться результати обчислювального експерименту

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)